Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO) Share Price

Price 133.50p on 18-07-2025 at 18:40:06
Change 1.00p 0.76%
Buy 135.00p
Sell 128.50p
Buy / Sell HEMO Shares
Last Trade: Sell 81.00 at 129.475p
Day's Volume: 17,512
Last Close: 131.75p
Open: 133.50p
ISIN: GB00BQVXM815
Day's Range 133.50p - 133.50p
52wk Range: 0.876p - 420.00p
Market Capitalisation: £6.13m
VWAP: 133.42971p
Shares in Issue: 4.59m

Hemogenyx (HEMO) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 81 129.475p Ordinary
16:25:06 - 18-Jul-25
Buy* 1,835 135.1701p Ordinary
15:30:49 - 18-Jul-25
Buy* 500 134.805p Ordinary
14:48:18 - 18-Jul-25
Buy* 2 135.00p SI Trade
14:26:50 - 18-Jul-25
Sell* 228 129.475p Ordinary
14:00:17 - 18-Jul-25
Buy* 22 134.68p Ordinary
11:38:39 - 18-Jul-25
Buy* 15 135.00p SI Trade
11:26:03 - 18-Jul-25
Buy* 20 135.00p SI Trade
11:26:03 - 18-Jul-25
Buy* 56 135.00p SI Trade
11:13:42 - 18-Jul-25
Buy* 1,500 133.50p Automatic Execution
11:13:42 - 18-Jul-25
See more Hemogenyx trades

Hemogenyx (HEMO) Share Price History

Time period:
to
Date Open High Low Close Volume
18th Jul 2025 (Fri) 133.50 133.50 133.50 131.75 17,512
17th Jul 2025 (Thu) 132.50 132.50 132.50 130.75 6,569
16th Jul 2025 (Wed) 132.00 132.50 132.00 132.25 39,687
15th Jul 2025 (Tue) 144.50 144.50 124.50 130.00 268,702
14th Jul 2025 (Mon) 144.50 144.50 144.50 142.00 23,303
11th Jul 2025 (Fri) 145.00 145.00 142.00 142.25 37,988
10th Jul 2025 (Thu) 150.00 156.50 145.00 145.00 38,066
9th Jul 2025 (Wed) 153.25 153.25 153.25 153.25 15,568
8th Jul 2025 (Tue) 153.25 153.25 153.25 153.25 14,505
7th Jul 2025 (Mon) 150.00 150.00 150.00 153.25 10,872
4th Jul 2025 (Fri) 153.25 153.25 153.25 153.25 91,796
3rd Jul 2025 (Thu) 156.50 156.50 156.50 153.25 8,271
2nd Jul 2025 (Wed) 153.25 153.25 153.25 153.25 30,048
1st Jul 2025 (Tue) 153.25 153.25 153.25 153.25 25,856
30th Jun 2025 (Mon) 153.25 153.25 153.25 153.25 42,813
27th Jun 2025 (Fri) 150.00 150.00 150.00 153.25 102,667
26th Jun 2025 (Thu) 152.25 154.25 152.25 154.25 37,398
25th Jun 2025 (Wed) 165.00 165.00 154.00 152.25 64,829
24th Jun 2025 (Tue) 168.50 168.50 168.50 169.25 8,271
23rd Jun 2025 (Mon) 177.50 177.50 177.50 169.75 21,123
20th Jun 2025 (Fri) 170.00 170.00 170.00 172.25 4,852
19th Jun 2025 (Thu) 173.75 175.00 173.75 175.00 3,151
See more Hemogenyx price history

Hemogenyx (HEMO) Regulatory News

Date Source Headline
16th Jul 2025 7:00 am RNS Hemogenyx Awarded Grant
30th Jun 2025 7:00 am RNS Total Voting Rights
17th Jun 2025 7:00 am RNS Clearance to Proceed with Pediatric Expansion
3rd Jun 2025 2:02 pm RNS Placing to Raise £451,250 and Director’s Dealing
3rd Jun 2025 7:00 am RNS Second Patient Passes Initial Safety Tests
30th May 2025 3:14 pm RNS Total Voting Rights
29th May 2025 2:06 pm RNS Result of AGM
14th May 2025 7:00 am RNS-R Pediatric Amendment to Clinical Protocol
13th May 2025 7:00 am RNS AGM Correction
8th May 2025 7:00 am RNS Placing to Raise £451,250 and Director’s Dealing
See more Hemogenyx regulatory news

Hemogenyx (HEMO) Share News

TRADING UPDATES: Journeo, Physiomics and Synectics win contracts

16th Jul 2025 14:34

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and Tuesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Safestay mulls asset sale; Sound Energy inks 2 deals

17th Jun 2025 15:48

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Valereum invests in Blubird; Hemogenyx raises funds

3rd Jun 2025 22:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

22nd May 2025 14:05

Read More

IN BRIEF: Hemogenyx expands trial to include paediatric patients

14th May 2025 14:28

Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Says it has filed, with the US Food & Drug Administration, an amendment to the clinical protocol for its ongoing phase 1 clinical trial of HG-CT-1 to include paediatric patients with relapsed/refractory acute myeloid leukemia, or R/R AML. CAR-T therapy HG-CT-1 is currently undergoing clinical trials to treat R/R AML in adults. Company says the amendment "seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting". Adds that expanding eligibility reflects its commitment to broadening the potential impact of HG-CT-1, and to addressing a critical unmet medical need in paediatric oncology. Read More

See more Hemogenyx news
FTSE 100 Latest
Value8,992.12
Change19.48

Login to your account

Forgot Password?

Not Registered